- Home
- CLOV vs GHRS Comparison
CLOV vs GHRS Comparison
Compare CLOV & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLOV | GHRS |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLOV | GHRS |
|---|---|---|
| Price | $2.24 | $15.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $3.35 | ★ $32.90 |
| AVG Volume (30 Days) | ★ 6.2M | 686.9K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,773,564,000.00 | N/A |
| Revenue This Year | $41.68 | N/A |
| Revenue Next Year | $43.92 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.15 | N/A |
| 52 Week Low | $2.12 | $7.98 |
| 52 Week High | $4.80 | $20.50 |
Technical Indicators
Market Signals| Indicator | CLOV | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 36.71 | 50.96 |
| Support Level | $2.45 | $15.50 |
| Resistance Level | $2.73 | $16.48 |
| Average True Range (ATR) | 0.14 | 0.94 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 5.22 | 33.33 |
Price Performance
Historical ComparisonAbout CLOV Clover Health Investments Corp.
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.